From: A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
Response
Number of patients
%
Complete response
0
Partial response
6
19.3
Stable disease
17
54.8
Progressive disease
8
25.9
Response Rate
19.3% (95% CI, 9.1%–36.2%) (90% CI, 10.3%–33.2%)
Disease control rate
25
74.1